CORDIS
EU research results

CORDIS

English EN

Concerted Safety & Efficiency Evaluation of Retroviral Transgenesis in Gene Therapy of Inherited Diseases

Objective

CONSERT will integrate leading European activities for a structured implementation of novel therapies using genetically enhanced postnatal stem cells, with focus on the treatment of monogenic immunodeficiencies, hemoglobinopathies, anemias and storage disorders.
CONSERT will develop and evaluate methods for genetic stem cell modification with wide implications for many other disorders including viral infection and cancer. A central theme of the project is an unbiased safety and efficiency evaluation of the key technology used in the genetic modifications of replicating somatic cells: retroviral vector-mediated transgenesis. This is only possible through concerted multi-center studies. Lenti-, spuma- and gamma-retroviral vectors will be tailor-made for target disorders and tested for potency and safety in preclinical disease models. Designed with a translational aim, basic studies in stem cell biology and selectable marker technology will complement this research. A most important aspect of CONSERT is the molecular and clinical monitoring of currently active and successful clinical trials of genetic therapies. This will create a paradigmatic data-mining activity to obtain insights into crucial issues of clonal kinetics of gene-modified cells in vivo. Molecular studies in precise cell systems and animal models will provide the mechanistic understanding of transgene-host interactions. This project will generate the basis for technology development and promote patient safety. Translational dissemination of know-how from academia to industry will create a network of cell processing manufacturers with large economic potential, and prepare future clinical studies with improved predictability. Supervised by a proactive ethical project, CONSERT will stimulate a competitive and complementary evolution of biomedical academia, clinics, innovative health service providers, and associated training opportunities.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM

Address

Dr Molewaterplein 50
Rotterdam

Netherlands

Administrative Contact

Gerard WAGEMAKER (Professor)

Participants (23)

Sort alphabetically

Expand all

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

EUROPAEISCHES INSTITUT FUR FORSCHUNG UND ENTWICKLUNG VON TRANSPLANTATIONSSTRATEGIE AG

Germany

INSTITUT FUR WISSENSCHAFT UND ETHIK E.V.

Germany

GATC BIOTECH AG

Germany

BANC DE SANG I TEIXITS

Spain

CENTRO DE INVESTIGACIONES ENERGETICAS MEDIAMBIENTALES Y TECHNOLOGICAS

Spain

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICINALE

France

GENETHON

France

GENOMINING

France

NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS

Greece

MOLECULAR MEDICINE S.P.A.

Italy

FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

Italy

UNIVERSITA VITA-SALUTE SAN RAFFAELE

Italy

LOUISE VAN DEN BOS SCIENCE & TECHNOLOGY TRANSFER

Netherlands

LUNDS UNIVERSITET

Sweden

UNIVERSITY COLLEGE LONDON

United Kingdom

THE VICTORIA UNIVERSITY OF MANCHESTER

United Kingdom

FOUNDATION OF BIOMEDICAL RESEARCH

Greece

GEORG SPEYER HAUS

Germany

EUROPEAN GENETIC ALLIANCES' NETWORK

Belgium

DEUTSCHES KREBSFORSCHUNGSZENTRUM

Germany

ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE

Switzerland

UNIVERSITÄTSKLINIKUM FREIBURG

Germany

Project information

Grant agreement ID: 5242

  • Start date

    1 November 2004

  • End date

    30 April 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 14 939 700

  • EU contribution

    € 11 635 000

Coordinated by:

ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM

Netherlands